The ARIEL 2 study evaluated the effectiveness of rucaparib in recurrent, platinum-sensitive, high-grade ovarian carcinoma with either BRCA1 and BRCA2 (BRCA) mutations or genomic loss of heterozygosity (LOH) scores. This evidence concerns the gene BRCA1 and ovarian carcinoma.